Re-evaluating aspirin in the era of potent P2Y12 inhibitors: Ticagrelor monotherapy after percutaneous coronary intervention

doi:10.5497/wjp.115880

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 2

This Article

(2)

(0)

(10)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Pharmacology

ISSN

2220-3192

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Pharmacol. Sep 16, 2026; 15(2): 115880
Published online Sep 16, 2026. doi: 10.5497/wjp.115880

Full Size Figure Download Figure

Figure 1 Forest plot of comparison. A: Dual antiplatelet therapy (DAPT) vs single antiplatelet therapy (SAPT), outcome: Clinically relevant bleeding (Bleeding Academic Research Consortium 2/3/5); B: DAPT vs SAPT, outcome: Major bleeding; C: DAPT vs SAPT, outcome: Three-point major adverse cardiac event; D: DAPT vs SAPT, outcome: Net adverse clinical events. CI: Confidence interval.

Citation: Basit A, Aslam MH, Anwar MM, Sarwar MA, Akram A, Ismail Q, Iftikhar A, Haq M. Re-evaluating aspirin in the era of potent P2Y12 inhibitors: Ticagrelor monotherapy after percutaneous coronary intervention. World J Pharmacol 2026; 15(2): 115880
URL: https://www.wjgnet.com/2220-3192/full/v15/i2/115880.htm
DOI: https://dx.doi.org/10.5497/wjp.115880

Basit A, Aslam MH, Anwar MM, Sarwar MA, Akram A, Ismail Q, Iftikhar A, Haq M. Re-evaluating aspirin in the era of potent P2Y12 inhibitors: Ticagrelor monotherapy after percutaneous coronary intervention. World J Pharmacol 2026; 15(2): 115880 [DOI: 10.5497/wjp.115880]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.